摘要
随着肿瘤学中免疫治疗的迅速发展,免疫检查点抑制剂(ICI)已在肿瘤治疗领域扮演了极其重要的角色。针对细胞毒性T淋巴细胞相关抗原-4、程序性细胞死亡受体-1及其配体程序性死亡配体-1等免疫检查点的抑制剂被广泛应用于各种肿瘤,其患者生存率显著提升的同时,也出现一系列的免疫相关不良反应,而ICI相关心肌炎是其中致死率最高的一种。现就ICI相关心肌炎的诊断及管理研究进展进行综述。
With the rapid development of immunotherapy in oncology,immune checkpoint inhibitor(ICI)have played an extremely important role in the field of oncology treatment.Inhibitors of immune checkpoints such as cytotoxic T lymphocyte-associated antigen-4,programmed cell death receptor-1 and its ligand programmed death ligand-1 are widely used in various cancers,and while the survival rate of tumour patients has increased significantly,a series of immune-related adverse effects have also emerged,with ICI-associated myocarditis being one of the most lethal.This article reviews the progress of research on the diagnosis and management of ICI-associated myocarditis.
作者
代虎威
曹慧丽
王馨焱
李松珊
温泽宇
曾康
杨滨
DAI Huwei;CAO Huili;WANG Xinyan;LI Songshan;WEN Zeyu;ZENG Kang;YANG Bin(Shanxi Medical University,Taiyuan 030000,Shanxi,China;Department of Cardiovascular Medicine,Second Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi,China)
出处
《心血管病学进展》
CAS
2022年第10期937-941,共5页
Advances in Cardiovascular Diseases
基金
山西省卫生健康委科研课题基金(2020071)。
关键词
免疫检查点抑制剂
心肌炎
心脏毒性
Immune checkpoint inhibitor
Myocarditis
Cardiotoxicity
